Clinical trials: Cytokine Release Syndrome
Covid-19, SARS
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Some patients infected with the COVID-19 can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. Tocilizumab was first approved by the U.S.
- Conditions
- Covid-19, SARS, Cytokine Storm, Cytokine Release Syndrome
- Trial name
- TACOS (NCT04306705)
- Testing
- Tocilizumab, Standard of care, Continuous renal replacement therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Covid19, Cytokine Storm
Menstrual Blood Stem Cells in Severe Covid-19
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of menstrual blood stem cells.
- Trial name
- NCT05019287
- Testing
- Allogeneic human menstrual blood stem cells secretome, Intravenous saline injection
- Where
- Iran
- Volunteers
- 29 people
- Sponsor
- Avicenna Research Institute
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Cardiac Surgery Recovery, Inflammation
Jafron Cytokine Adsorber During Pediatric Open-Heart Surgeries
This prospective single-center randomized controlled trial aims at evaluating the safety and feasibility of an hemoadsorption protocol using Jafron HA-60 during cardio-pulmonary bypass in 20 pediatric patients undergoing…
- Conditions
- Cardiac Surgery Recovery, Inflammation, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Cytokine Storm
- Trial name
- JACKPOT (NCT07393087)
- Testing
- Hemoadsorption
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
COVID 19
Oral 25-hydroxyvitamin D3 and COVID-19
The goal of this clinical trial is to investigate the therapeutic efficacy of rapidly correcting vitamin D deficiency in adults with the use of 25-hydroxyvitamin D3 [25(OH)D3] for reducing the risk of acquiring the SARS-CoV-2…
- Trial name
- NCT04386850
- Testing
- Oral 25-Hydroxyvitamin D3
- Where
- Iran
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
COVID-19
Safety and Efficacy of Baricitinib for COVID-19
This study plans to learn more about the effects of a medicine called baricitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT04340232
- Testing
- Baricitinib
- Where
- United States
- Sponsor
- University of Colorado, Denver
Cardiac Arrest, Extracorporeal Circulation
Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation
Almost all patients with refractory cardiac arrest, who are primarily stabilized under ongoing cardiopulmonary resuscitation by transcutaneous implantation of a venoarterial extracorporeal membrane oxygenation system (va-ECMO for…
- Conditions
- Cardiac Arrest, Extracorporeal Circulation, Extracorporeal Membrane Oxygenation, Cytokine Storm
- Trial name
- CYTER (NCT03685383)
- Testing
- Cytosorb removal column in eCPR, standard eCPR (va-ECMO)
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- University Hospital Freiburg
Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-Cov-2
Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic
During the COVID-19 pandemic, a small minority of children have been presenting to acute paediatric services with a new syndrome, Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-Cov-2 (PIMS-TS).
- Trial name
- NCT04761913
- Where
- 6 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Anglia Ruskin University
Disease, Viral, Cytokine Release Syndrome
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
To ascertain globally the changes in the cytokines involved and TLRs/KIR activation in patients admitted to the hospital with a COVID-19 diagnosis, and the changes after initiation of the different therapies
- Conditions
- Disease, Viral, Cytokine Release Syndrome, TLRs
- Trial name
- Resistir (NCT04403061)
- Testing
- Cytokines measurement, Cellular response, TLRs activation measurement
- Where
- Spain
- Volunteers
- 106 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
Cytokine Release Syndrome, Recurrent Multiple Myeloma
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period…
- Conditions
- Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07657312
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Naresh Bumma
Sepsis, Sepsis Bacterial
Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
This observational cohort study aims to compare clinical outcomes and inflammatory responses between patients with viral sepsis, specifically COVID-19-associated sepsis, and those with bacterial sepsis.
- Conditions
- Sepsis, Sepsis Bacterial, Viral Sepsis, Inflammatory Response
- Trial name
- NCT06491966
- Testing
- observation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sichuan Provincial People's Hospital
COVID-19, Cytokine Release Syndrome
Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;
Background: investigators have seen recently from experience in Western countries with best health care systems that pandemics cannot be managed in hospitals.
- Trial name
- Plex (NCT04485169)
- Testing
- Therapeutic Plasma Exchange
- Where
- Pakistan
- Volunteers
- 280 people
- Sponsor
- UNICEF
Morbid Obesity, Opioid Use
Inflammatory Response to Opioid Versus Opioid Free Anesthesia
Anesthetic agents, including opioids can modulate the altered immune function in patients with obesity through mechanisms that involve the expression and release of cytokines.
- Conditions
- Morbid Obesity, Opioid Use, Fentanyl Adverse Reaction, Cytokine Storm
- Trial name
- NCT04854252
- Testing
- Fentanyl
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- University of Guadalajara
Cytokine Release Syndrome, CAR-T
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)
Patients with severe CAR-T cell associated cytokine release syndrome (CRS) (defined as vasopressor dependent) will be treated with standard of care (SOC) + cytokine adsorption (6hourly for 24 hrs).
- Trial name
- CYTORELEASE (NCT04048434)
- Testing
- Cytosorb
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 34 people
- Sponsor
- Hannover Medical School
Burns, Growth Factors, Combined Defect of
Keratinocyte Growth Factor and Cytokines in Burns.
KERATINOCYTE GROWTH FACTOR AND CYTOKINES IN SKIN BURNS. INTRODUCTION: Intense inflammatory responses are activated by burns that affect a large total body surface area.
- Conditions
- Burns, Growth Factors, Combined Defect of, Inflammation, Cytokine Storm
- Trial name
- NCT01302223
- Where
- Brazil
- Volunteers
- 8 people
- Sponsor
- Federal University of São Paulo
Acute Lung Injury, Acute Respiratory Distress Syndrome
Airway Pressure Release Ventilation in Acute Lung Injury
The purpose of this study is to compare airway pressure release ventilation (APRV) to conventional mechanical ventilation (MV) in patients with acute lung injury (ALI) to determine if APRV can reduce agitation, delirium, and…
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Mechanical Ventilation
- Trial name
- NCT00750204
- Testing
- APRV, Conventional MV
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
Intensive Care Units, ARDS, Human
Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections
Severe Covid-19 (Coronavirus Disease 2019) infections generate major but inappropriate production of cytokines and, in some cases, generate anti-IFN (Interferon) auto-antibodies, inducing acute respiratory distress syndrom…
- Conditions
- Intensive Care Units, ARDS, Human, Covid19
- Trial name
- CovidEP (NCT04751643)
- Testing
- Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3), Usual treatments in intensive care unit according to the current state of knowledge
- Where
- 8 sites in France
- Volunteers
- 21 people
- Sponsor
- Hospices Civils de Lyon
COVID-19, Pneumonia
Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study
This pilot case-control study at Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram, India is designed to evaluate the use of low dose radiotherapy (LDRT) in patients with moderate COVID-19 with specific objectives to…
- Trial name
- LOCORAD (NCT04904783)
- Testing
- Low dose radiotherapy
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Mahatma Gandhi Institute of Medical Sciences
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC